
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
The Q3 recap for gastroenterology spotlights key FDA decisions, new AGA gastroparesis guidelines, and other top GI news and research.
The third quarter of 2025 brought several regulatory updates, announcements of clinical trial data, and new guidelines in gastroenterology.






